An Observational, Prospective, Real-World Study of Tislelizumab as Neoadjuvant Therapy for dMMR/MSI-H Stage II-III Colorectal Cancer
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Tislelizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Feb 2026 Status changed from not yet recruiting to recruiting.
- 29 Jan 2026 New trial record